The purpose of this study was to evaluate the relevance for the prediction of clinical benefit of first-line treatment with erlotinib using different quantitative parameters for PET with both 18 F-FDG and 39-deoxy-39-18 F-fluorothymidine ( 18 F-FLT) in patients with advanced non-small cell lung cancer. Methods: Data were used from a prospective trial involving patients with untreated stage IV non-small cell lung cancer. 18

In patients with advanced NSCLC, percentage changes of TLG and TLP and absolute residual TLG and TLP levels under erlotinib treatment emerged as strong predictive factors for PFS. Our findings indicate that a cutoff value of 20% or 30% for definition of metabolic response measured by percentage changes of TLG and TLP provides suitable results for response prediction, which should be further validated.

Early and late residual FDG uptake, measured using different quantitative SUV parameters, are predictive factors for short-term outcome in patients with advanced NSCLC treated with erlotinib. Additionally, low residual FDG and FLT uptake early and late in the course of erlotinib treatment is associated with improved PFS.

No abstract

No abstract

T2 and T2* mapping of the hip in patients after SCFE are significantly different from healthy controls and may offer additional information about cartilage quality.

Prognostic study, Level II-1 (retrospective study).

The data support an anterosuperior and superior cam-type deformity of the femoral head-neck junction in the follow-up after SCFE. MRI after SCFE can be used to assess anterosuperior and superior alpha angles, since the anterior alpha angle by itself may underestimate asphericity and is not associated with rotation deficits.